Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France
European Journal of Public Health · 2024
DOI: 10.1093/eurpub/ckae131 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Public Health, 2024. Verfasst von Morgane Cabon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Haemophilia Treatment Centre and French Reference Centre on Haemophilia, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Health Services Accessibility, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: laboratories Roche-Chugai, Hospices Civils of Lyon.
Abstract (Originalsprache)
Since June 2021 in France, patients with haemophilia A with anti-factor VIII inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the choice between the community and the hospital pharmacy for dispensing emicizumab (Hemlibra®). This study aims to investigate patient-centred access to treatment by evaluating and comparing the dimensions of the Penchansky and Thomas model, between community and hospital pharmacies. The evaluation of access to treatment was based on the dimensions of the Penchansky and Thomas model: accessibility, availability, acceptability, accommodation and affordability. These were assessed using appropriate and specific indicators in the study context and calculated for patients choosing community pharmacy or hospital pharmacy for emicizumab dispensing. Geographical data collected as part of the national ‘PASO DOBLE DEMI’ study were used for this analysis. The findings reveal that dispensing emicizumab in community pharmacies improves accessibility by significantly reducing travel time. The availability of healthcare services is also improved due to the territorial coverage of community pharmacies. The extended opening hours and low waiting time also contribute to better access to emicizumab in community pharmacies. The dimension of acceptability must be improved, and further investigations are needed to address the affordability dimension. Several months after emicizumab became available in French community pharmacies, access to treatment has significantly improved, reducing the burden of this rare chronic disease for patients and their careers. These results suggest that this innovative model could be extended to other medicines and even other therapeutic areas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Haemophilia Treatment Centre and French Reference Centre on Haemophilia, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France.
- Pharmaceutical Unit, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France.
- Research on Healthcare Performance RESHAPE, INSERM U1290, University Claude Bernard Lyon 1, Lyon, France.
- Laboratory P2S (Health Systemic Process), UR 4129, Faculty of Medicine Laennec, University Claude Bernard Lyon 1, Lyon, France.
ORCID-Profile: Laurie Fraticelli
Förderung
- laboratories Roche-Chugai
- Hospices Civils of Lyon
Zitieren
APA
Cabon, M., Chamouard, V., Freyssenge, J., & Fraticelli, L. (2024). Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France. European Journal of Public Health. https://doi.org/10.1093/eurpub/ckae131
Vancouver
Cabon M, Chamouard V, Freyssenge J, Fraticelli L. Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France. European Journal of Public Health. 2024. doi:10.1093/eurpub/ckae131
BibTeX
@article{Cabon2024,
author = {Cabon, Morgane and Chamouard, Valérie and Freyssenge, Julie and Fraticelli, Laurie},
title = {Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France},
journal = {European Journal of Public Health},
year = {2024},
doi = {10.1093/eurpub/ckae131}
}
EUVIMED